Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
SMARTSCORE: 3/5
Celltrion Inc (068270 KS)
Watchlist
Contact IR
597
Analysis
Health Care
•
South Korea
Celltrion Inc. produces and sells biosimilar products and also provides consignm ent processing service for other companies. The Company's main product is Abata cept which is for arthritis treatment
more
Watchlist
Contact IR
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
01 Jun 2025 00:30
APAC Healthcare Weekly (June 1)- Eisai, Daiichi, Samsung Bio, SK Bioscience, CSPC, Hengrui Pharma
Eisai's Dayvigo approved in China. Daiichi Sankyo withdrew BLA in US. Samsung Bio secures CMO contracts. SK Bioscience expands vaccine...
Tina Banerjee
Follow
457 Views
Share
bullish
•
HD Hyundai
•
28 May 2025 05:03
Korea Value Up: Outperformance Relative to KOSPI200 & KOSDAQ150 Likely to Attract Greater Capital
Korea Value Up index is up 8.2% from 30 September 2024 to 28 May 2025, outperforming KOSPI 200 (up 3.4%) and KOSDAQ 150 (down 7.9%) in the same...
Douglas Kim
Follow
272 Views
Share
bearish
•
Quantitative Analysis
•
27 May 2025 23:05
KRX Short Interest Weekly (May 23rd): Celltrion, Hanmi Semi, Meritz Financi
We analyzed KRX short interest report for the past week and highlighted short interest changes in Celltrion (068270 KS), Hanmi Semi (042700 KS),...
Ke Yan, CFA, FRM
Follow
215 Views
Share
bullish
•
Quantitative Analysis
•
25 May 2025 23:15
KRX Foreign Holding Weekly (May 23rd): Hyosung Heavy, SK Hynix, Samsung Electronics
We analyzed KRX foreign holding data for the past week and highlighted foreign holding changes in Hyosung Heavy, SK Hynix, Samsung Electronics.
Ke Yan, CFA, FRM
Follow
304 Views
Share
bullish
•
Thematic (Sector/Industry)
•
25 May 2025 00:30
APAC Healthcare Weekly (May 25)- 3SBio, Samsung Biologics, Celltrion, CSPC Pharma, Chugai
APAC healthcare companies continued to get approvals for new products and initiates clinical trials. The companies continued with acquisitions and...
Tina Banerjee
Follow
581 Views
Share
First
Previous
4
5
6
7
8
9
10
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.55.4
x